Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome
Status:
Recruiting
Trial end date:
2023-05-24
Target enrollment:
Participant gender:
Summary
The main objective is to demonstrate, from the initial episode of nephrotic syndrome (NS) in
children with standard prednisolone treatment, once complete remission has occurred, that the
use of Rituximab (a single intravenous infusion of 375 mg/m2) may reduce the risk of
subsequent relapse during 12-month of follow-up.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital of Fudan University
Collaborators:
Anhui Provincial Children's Hospital Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital Children's Hospital of Nanjing Medical University Henan Provincial People's Hospital Shanghai Children's Hospital The Children's Hospital of Zhejiang University School of Medicine Wuhan Union Hospital, China Xinhua Hospital, Shanghai Jiao Tong University School of Medicine